Citron alleged Valeant used a captive specialty pharmacy network, principally Philidor, to create phantom sales and inflate reported revenue — likening the structure to Enron's off-balance-sheet entities.
We did not write this report. We catalogued it. The underlying research was published by Citron Research. The Forensic Ledger does not endorse its conclusions. Always read the original document.
The distribution black box
Valeant's growth depended on a specialty pharmacy channel it publicly described as arm's-length. The reports argued the relationship was anything but.
Findings
- Philidor operated as a de facto captive channel, consolidated but presented as independent
- Related pharmacy entities appeared to exist to book product into a channel, not to a patient
- Price-and-acquire model masked negligible organic growth beneath serial M&A accounting
The conclusion
A roll-up whose reported growth depended on the accounting treatment of its own distribution, not on end demand.
subsequent events
- 2015-10-21Report published; shares fall ~19% intraday
“Valeant is creating phantom accounts to book non-existent revenue.”
- 2015-10-30Valeant severs ties with Philidor
- 2016-03-21CEO departure announced; financials restated
Source — https://citronresearch.com/
Not investment advice. This dossier summarizes a third-party short report. The Forensic Ledger did not produce the underlying research and does not endorse its conclusions. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.